Le Lézard
Classified in: Science and technology
Subjects: Photo/Multimedia, Product/Service

Kraken Launches Licensed Broker Offering for Australian Wholesale Clients


Kraken, one of the world's longest-standing and most secure crypto platforms, has today unveiled a new offering that will service Australian wholesale clients with a suite of crypto-based derivatives products.

From today, Kraken will enable wholesale clients to acquire crypto-based derivatives via its Australian financial services licensed broker. The derivatives broker offering will provide flexibility and depth empowering eligible clients to manage risk and gain exposure to crypto price movements without holding the underlying assets.

"Over our 13 year history, we have always aspired to be one step ahead of market demand. Australian wholesale clients are looking for the ability to execute advanced trading strategies using a licensed broker backed by Kraken's high security standards," said Jonathon Miller, Kraken's GM for Australia and Rest of World. "Our new premium product meets our clients' trading needs, and helps them to advance in their crypto journey."

With over 200 tradable assets, Kraken will offer multi-collateral support (including fiat, stablecoin and crypto) that is held in one of the most robust crypto custodial solutions available in the market and comes with round-the-clock client support services.

Miller added, "Australia has long been a cornerstone of Kraken's global operation. Our licensed broker offering is testament to our ongoing commitment to regulatory compliance and to bring exciting crypto products to market that can truly unlock institutional demand for cryptoassets."

Prospective Australian wholesale clients can explore this new offering via Kraken's Support page. Existing Australian wholesale clients can confirm their eligibility to access this new offering directly from the Kraken Pro app.

About Kraken:

Kraken is one of the world's longest-standing and most secure crypto platforms. Our mission is to accelerate the global adoption of crypto, so that everyone can achieve financial freedom and inclusion. Globally, through Kraken's digital currency exchange, clients trade more than 200 crypto assets and 6 different national currencies, including AUD, USD, EUR, GBP, CAD, and CHF.

Founded in 2011, Kraken was among the first digital currency exchanges to offer a broad range of services like (depending on jurisdiction) spot trading with margin, parachain auctions, staking and derivatives and index services under one roof. With millions of individuals, traders and institutions around the world, Kraken offers professional 24/7/365 client support along with one of the fastest, most performant trading platforms available. Kraken strived to set the industry standard for transparency and client trust, and was the first crypto platform to conduct Proof of Reserves. In 2024, Kraken ranked 14th in Newsweek's Top 100 Global Most Loved Workplaces showcasing how the platform offers one of the most compelling employment opportunities.

For more information about Kraken, please visit www.kraken.com.


These press releases may also interest you

at 15:30
Anthony "Tony" Van Heugten, the Chief Technology...

at 15:05
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...

at 15:00
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...



News published on and distributed by: